Evonik REXIM has entered into an agreement with Brenntag Specialties Pharma for the exclusive distribution of its REXIM® GMP-grade amino acids across most of Europe. Under the agreement, Brenntag will assume responsibility for market development and distribution in key regions including the DACH region, the UK, France, Benelux, Scandinavia, Central and Eastern Europe, Israel and Turkey. Italy, Ukraine, the Middle East and Africa are excluded from the agreement.
“Our agreement with Brenntag significantly strengthens the market reach for our REXIM® amino acids,” said Thomas Hermann, head of the REXIM product line at Evonik Health Care. “Brenntag’s strong regional footprint, deep customer relationships, and extensive experience in the life-science sector make them an ideal partner. Together, we can provide customers with reliable access to high-quality GMP-grade amino acids and support the fast-growing pharmaceutical and biopharmaceutical markets.”
Evonik REXIM is a leading supplier of high-quality amino acids, with key production capabilities and supply sources located in Europe. The company combines market leadership in fermentation, bioconversion and synthetic-based manufacturing. Its collaboration with Brenntag supports Evonik’s ambition for the REXIM® portfolio, expanding its presence in key global markets and providing customers with enhanced local service, technical support, and long-term supply security.
“Our collaboration with Evonik reflects Brenntag’s commitment to bringing high-value pharmaceutical ingredients and solutions closer to our customers,” said Joakim Rehné, President Brenntag Pharma EMEA. “By combining Evonik’s world-class expertise in GMP-grade amino acids with Brenntag’s extensive market presence, technical capabilities, and regulatory know-how, we are uniquely positioned to support the evolving needs of pharmaceutical and biopharmaceutical manufacturers across the region. Together, we are creating a stronger, more reliable supply network that helps accelerate innovation and ensure patient access to critical therapies.”
Amino acids are fundamental building blocks of life and essential components of proteins, driving key biochemical and metabolic processes. REXIM® provides highly purified natural and non‑natural amino acids. Their high quality and reliability make them suitable for a wide range of regulated applications, including medical nutrition, active pharmaceutical ingredients (APIs) and excipients, as well as nutrient components for cell culture media used in biopharmaceutical production.
As a partner to the pharmaceutical industry, Evonik offers a broad, versatile portfolio of functional excipients, technologies, and contract manufacturing (CDMO) services for oral and parenteral dosage forms. End-to-end CDMO capabilities for small molecule APIs, highly potent APIs and intermediates, as well as high-quality innovative cell culture solutions (e.g., dipeptides, lipids, carbohydrates, surfactants) are also a cornerstone in Evonik’s Health Care portfolio.
